Allgenesis Biotherapeutics Inc. is focused on developing innovative therapies for ocular conditions, particularly diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). Their lead candidate, AG-73305, is a bispecific anti-VEGF and anti-integrin Fc-fusion protein designed to address the underlying mechanisms of these diseases. The company has reported promising preliminary safety and efficacy data from its Phase 2a clinical trials, indicating that AG-73305 may provide significant benefits for patients suffering from DME. This therapy aims to improve vision by targeting the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), which are implicated in the pathogenesis of nAMD.

In addition to AG-73305, Allgenesis is also advancing AG-80308, which has shown encouraging results in Phase 1b trials for dry eye patients. The company recognizes the limitations of current anti-VEGF therapies, which often fail to provide adequate responses in a significant portion of patients and can lead to treatment burdens due to the need for frequent injections. By developing novel therapies that target multiple mechanisms of retinal disease, Allgenesis aims to meet the unmet medical needs of patients with these debilitating eye conditions, ultimately improving their quality of life and vision outcomes.

Taiwan

Allgenesis is a privately-held, clinical stage ophthalmology company based in Taiwan. The company is focused on novel multi-specific fusion proteins for treating diabetic macular edema and wet-age-related macular degeneration; and small molecule eye drops for dry eye and pterygium diseases.

Allgenesis Biotherapeutics Inc.

Company Details